Radient Pharma (RPC) Issues FY10 Results; 10-K Contains 'Going Concern'
Radient Pharmaceuticals Corp (AMEX: RPC) reports FY10 loss of $2.88 per share. Revenue for the quarter was $231,662, compared to $158,017 in FY09.
RPC's Annual Report on Form 10-K included an audit opinion with a "going concern" explanatory paragraph which expresses doubt, based upon current financial resources, as to whether RPC can meet its continuing obligations without access to additional working capital. The Company intends to raise additional capital and pursue expense reductions to ensure its ongoing financial viability.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
RPC's Annual Report on Form 10-K included an audit opinion with a "going concern" explanatory paragraph which expresses doubt, based upon current financial resources, as to whether RPC can meet its continuing obligations without access to additional working capital. The Company intends to raise additional capital and pursue expense reductions to ensure its ongoing financial viability.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Semtech Corp (SMTC) Misses Q1 EPS by 4c; Guides Q2
- AFC Enterprises, Inc. (AFCE) Tops Q1 EPS by 4c; Raises FY12 Comps Outlook
Create E-mail Alert Related Categories
EarningsComments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
RPC
Card Expressions on May 25, 2011 01:37 PMMark as Spam
HOW can a company go from 15,000 a share to .20 what makes this happen?